SAN JOSE, Calif., Oct. 17, 2025 Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a pioneering clinical-stage biotherapeutics company dedicated to the oral delivery of biologics and pharmaceuticals, has officially announced a strategic partnership with Chugai Pharmaceutical Co., Ltd. The collaboration, which is valued at up to $1.085 billion, encompasses the development and commercialization of innovative therapies, focusing on Rani’s oral delivery technology paired with Chugai’s promising rare disease antibody.
The deal is expected to advance Rani’s proprietary RaniPill® technology, designed to facilitate the oral administration of biologics, a challenge that has long impeded the efficacy and convenience of these vital therapies. By leveraging each company’s strengths, the partnership aims to expedite the availability of new treatment options for patients suffering from rare diseases and various immunological disorders.
Rani Therapeutics’ CEO expressed optimism about the collaboration, emphasizing the potential transformative impact on patient treatment paradigms. “This collaboration with Chugai not only validates our approach to oral delivery technology but also highlights our commitment to addressing unmet medical needs in the field of rare diseases,” the CEO stated.
In addition to the collaboration announcement, Rani Therapeutics revealed a concurrent oversubscribed financing round, which successfully raised $60.3 million. The financing is intended to support the ongoing development of the company’s pipeline and strengthen its operational capabilities.
Financial metrics from Rani Therapeutics indicate stability in accounts receivable management, with the accounts receivable turnover ratio remaining unchanged at 8 for the second quarter of 2025, similar to the previous quarter. This stability indicates that while the business environment has become more challenging compared to earlier in the year, Rani Therapeutics continues to maintain proficient oversight of its receivables.
The average collection period for accounts receivable was consistent at 46 days as of June 30, 2025, ensuring the company maintains a strong liquidity position. While competitors within the healthcare sector showcase higher receivables turnover ratios, Rani’s ranking remains steady at number 8, reflecting its stability amidst industry fluctuations.
As Rani Therapeutics forges ahead with its promising collaborations and financing efforts, the industry is poised to watch closely how these initiatives will unfold and contribute to the therapeutic landscape for patients in need.
Comments